No Impact of HIV Coinfection on Mortality in Patients With Hepatitis C Virus Infection After Sustained Virological Response.

This study investigates the impact of human immunodeficiency virus (HIV) coinfection on long-term mortality in patients with chronic hepatitis C virus (HCV) infection and advanced liver fibrosis who achieved sustained virological response (SVR) after direct-acting antiviral (DAA) therapy. In a prospective multicenter cohort of 1,118 patients from Spain, including 676 with HIV/HCV coinfection, no significant difference in overall survival or liver-related and non–liver-related mortality was observed between coinfected and HCV-monoinfected individuals over a median follow-up of 76 months. Multivariate analyses adjusting for confounders confirmed that HIV coinfection was not associated with increased mortality, while factors such as age, prior liver decompensation, liver stiffness at SVR, and MELD score were predictive of death. The findings suggest that HIV coinfection does not reduce survival after HCV cure in patients with advanced fibrosis, although longer follow-up is needed to confirm these results.